Price movement over the last 24 hours
Alcon AG vs Marathon Petroleum Corp — how do they compare? Alcon AG trades at $66.96 (market cap $32.69B), while Marathon Petroleum Corp trades at $276.37 (market cap $77.75B). The key difference: Marathon Petroleum Corp is far larger — about 2.4× Alcon AG's market cap, and Marathon Petroleum Corp pays the higher dividend (1.47%). Which is the better fit depends on your goals.
| ALC | MPC | |
|---|---|---|
Market Cap | $32.69B | $77.75B |
Sector | Health | Energy |
52-Week High | $92.22 | $268.99 |
52-Week Low | $62.02 | $158.59 |
Enterprise Value | $36.28B | $109.93B |
Dividend Yield | 0.54% | 1.47% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Marathon Petroleum (MPC) trades at $266.33, showing minimal daily movement (-0.01%) but maintaining strong momentum with a 52% gain over the past six months. The stock demonstrates robust profitability with ROE of 27.92% and net income margin of 3.42%, supported by favorable refining margins from global supply disruptions. Recent earnings show mixed performance with Q3 2025 missing estimates but Q1 2026 beating expectations by 123%.
MPC presents a compelling investment case with attractive valuation (P/E 17.71, P/S 0.6) and strong analyst support (76% buy ratings). However, declining revenue trends from $177.5B in 2022 to $132.7B in 2025 and rising debt-to-asset ratio to 42.59% warrant caution. The upcoming Q2 2026 earnings on August 4th will be critical for validating the current bullish sentiment.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →